相关临床试验
90
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1956
进行中（未招募）
2
2.2%
已完成
77
85.6%
Enrolling By Invitation
2
2.2%
尚未招募
1
1.1%
招募中
4
4.4%
终止
2
2.2%
Unknown
1
1.1%
撤回
1
1.1%
暂无批准数据
- High Q Technologies, founded at the University of Waterloo in 2013, is developing a quantum sensor called Fathom that uses electron paramagnetic resonance (EPR) spectroscopy to map protein motion with extreme precision. - The Fathom platform aims to accelerate drug discovery for neurodegenerative diseases such as Alzheimer's by years and could significantly reduce resources required in drug testing stages. - EPR spectroscopy detects all protein configurations simultaneously, overcoming limitations of traditional techniques that struggle to resolve the full range of protein motion. - The company has partnered with Creative Biostructure, a contract research organization with over 3,000 customers across 60 countries, to expand global access to its quantum technology.
- Revive Therapeutics has partnered with Attwill Medical Solutions to develop a novel lyophilized formulation of Bucillamine, with enhanced solubility showing more than double improvement over standard formulations. - The company is preparing a Phase 2/3 clinical protocol for long COVID treatment, leveraging data from a previous Phase 3 trial that showed no hospitalizations in the high-dose Bucillamine group. - Long COVID affects 7.5% of U.S. adults with an estimated economic burden of $3.7 trillion, representing a significant unmet medical need for effective treatments. - Bucillamine's thiol-based mechanism decreases SARS-CoV-2 spike protein binding and inhibits viral cell entry, providing scientific rationale for its potential in treating COVID-related conditions.
